Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists

Abstract

Adverse effect of dopamine agonists on the heart valves aroused much attention some time ago. Gradually, as data accumulated, the approach to the problem was rationalised and further examinations were only recommended in indicated cases.

The paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease.

Keywords

• dopamine agonists
• ergolines/adverse effects
• heart valve diseases
• hyperprolactinemia
• pituitary neoplasms
• prolactinoma